相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial
Narek Shaverdian et al.
LANCET ONCOLOGY (2017)
Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
Stefan Diem et al.
LUNG CANCER (2017)
Immunotherapy comes of age: Immune aging & checkpoint inhibitors
Rawad Elias et al.
JOURNAL OF GERIATRIC ONCOLOGY (2017)
High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
J. Zaragoza et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
P. F. Ferrucci et al.
ANNALS OF ONCOLOGY (2016)
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
Yoshio Nakamura et al.
ONCOTARGET (2016)
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
P. F. Ferrucci et al.
BRITISH JOURNAL OF CANCER (2015)
Tumor-infiltrating lymphocytes predict cutaneous melanoma survival
Cristina Fortes et al.
MELANOMA RESEARCH (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Julie Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors
Xueli Bai et al.
SCIENTIFIC REPORTS (2015)
Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes
Alena Gros et al.
Journal for ImmunoTherapy of Cancer (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Chad Tang et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Treatment-related Lymphopenia in Patients With Stage III Non-Small-Cell Lung Cancer
Jian L. Campian et al.
CANCER INVESTIGATION (2013)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
分享论文
